Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Ocugen, Inc. before investing.

In this article, we go over a few key elements for understanding Ocugen, Inc.’s stock price such as:

• Ocugen, Inc.’s current stock price and volume
• Why Ocugen, Inc.’s stock price changed recently
• Upgrades and downgrades for OCGN from analysts
• OCGN’s stock price momentum as measured by its relative strength

About Ocugen, Inc. (OCGN)

Before we jump into Ocugen, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Want to learn more about Ocugen, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Ocugen, Inc..

Ocugen, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Ocugen, Inc.’s stock price was $1.230.

Ocugen, Inc. is down 2.38% from its previous closing price of $1.260.

During the last market session, Ocugen, Inc.’s stock traded between $1.230 and $1.300. Currently, there are approximately 327.54 million shares outstanding for Ocugen, Inc..

Ocugen, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Ocugen, Inc. Stock Price History

Ocugen, Inc.’s (OCGN) price is currently down 19.61% so far this month.

During the month of July, Ocugen, Inc.’s stock price has reached a high of $1.600 and a low of $1.170.

Over the last year, Ocugen, Inc. has hit prices as high as $2.725 and as low as $0.931. Year to date, Ocugen, Inc.’s stock is down 8.89%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Ocugen, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded Ocugen, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Ocugen, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Ocugen, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Ocugen, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Ocugen, Inc. (OCGN) by visiting AAII Stock Evaluator.

Relative Price Strength of Ocugen, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Ocugen, Inc. has a weighted four-quarter relative price strength of -3.81%, which translates to a Momentum Score of 40 and is considered to be Weak.

Want to learn more about how Ocugen, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Ocugen, Inc. Stock Price: Bottom Line

As of July 31, 2026, Ocugen, Inc.’s stock price is $1.230, which is down 2.38% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Ocugen, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.